Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
Humanstau ProteinsAlzheimer DiseaseFemaleReproducibility of ResultsMaleImmunoassayAmyloid beta-PeptidesCognitive DysfunctionAgedBiomarkersPhosphorylationPositron-Emission TomographyAged, 80 and overAlzheimer's diseaseFujirebio Lumipulseanalytical performancediagnostic accuracyplasma p‐tau217
Come citare questo studio
Susan Ashrafzadeh-Kian, Daniel J Figdore, Joshua A Bornhorst, Patrick M Vanderboom, Sarah Callison, Gregory S Day, Christian Lachner, Neill Graff-Radford, Dror Shir, Clifford R Jack, David S Knopman, Jonathan Graff-Radford, Ronald C Petersen, Vijay K Ramanan, Alicia Algeciras-Schimnich. (2026). Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice.. Alzheimer's & dementia : the journal of the Alzheimer's Association. DOI: 10.1002/alz.71887
Consulta la pubblicazione originale ↗